One of the most notable achievements of 2023 was the approval of a disease-modifying Alzheimer’s drug, representing a breakthrough in the decades-long quest to combat this debilitating condition. Developed by Eisai and Biogen, the amyloid-fighting antibody Leqembi offers hope to millions affected by Alzheimer’s and their families. Moreover, the approval of Leqembi reflects a renewed focus on addressing complex neurological disorders, signaling a shift towards tackling previously untreatable conditions.
The FDA’s approval landscape in 2023 also highlighted the growing prominence of biologic therapies, with nearly half of the newly approved drugs falling into this category. This trend underscores the increasing utilization of advanced biologic modalities and the expanding capabilities of biotechnology in addressing diverse medical needs. Furthermore, the approval of multiple orphan drugs for rare diseases emphasizes the importance of targeted therapies in addressing unmet medical needs within smaller patient populations.
Despite the remarkable progress made in 2023, the FDA faced challenges such as delays due to COVID-19-related constraints and contentious decision-making processes. However, the agency’s commitment to advancing public health and fostering innovation remained steadfast, paving the way for a new era of medical breakthroughs. As we look ahead to 2024, anticipation mounts for further advancements in drug development and the potential for additional groundbreaking therapies to transform patient care and improve outcomes across a spectrum of diseases.
https://www.nature.com/articles/s41587-024-02166-7
Check out our mRNA service to expedite your vaccine research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Exploring Tau Protein’s Role in Glaucoma: New Insights and Therapeutic Potential
Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying...
FDA-mandated CAR-T monitoring period could be halved, say researchers
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study...
Ancestral CRISPR-Cas13 Ribonucleases Discovered: Implications for Genome Editing
In a pioneering study published in *Science*, a team of researchers led by Peter H. Yoon and Jennifer A. Doudna from the University of California, Berkeley, has made a remarkable discovery in the realm of CRISPR technology. The team has identified an ancestral clade...
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed...
Related Services
Plasmids GMP Services
AAV GMP Services
